Edition:
United Kingdom

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

125.83USD
18 Oct 2018
Change (% chg)

-- (--)
Prev Close
$125.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
148,986
52-wk High
$152.55
52-wk Low
$100.64

Chart for

About

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH):... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $5,381.27
Shares Outstanding(Mil.): 43.44
Dividend: --
Yield (%): --

Financials

  UTHR.OQ Industry Sector
P/E (TTM): 14.44 85.83 33.69
EPS (TTM): 8.58 -- --
ROI: 20.98 0.58 14.30
ROE: 21.85 1.62 16.03

BRIEF-United Therapeutics Reports Q1 Adj. Earnings Per Share Of $3.76

* Q1 EARNINGS PER SHARE VIEW $3.52 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-United Therapeutics To Acquire SteadyMed Ltd

* UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION

30 Apr 2018

BRIEF-United Therapeutics Says CEO Martine Rothblatt's FY 2017 Total Compensation Was $37.1 Mln

* UNITED THERAPEUTICS SAYS CEO MARTINE ROTHBLATT'S FY 2017 TOTAL COMPENSATION WAS $37.1 MILLION WHICH INCLUDED $33.1 MILLION IN OPTION/STAP AWARDS - SEC FILING

27 Apr 2018

Earnings vs. Estimates